Article Text

Download PDFPDF

Journal club summaries
What's hot that the other lot got
  1. J Elshof1,2
  1. 1 Department of Pulmonary Diseases/Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  2. 2 Groningen Research Institute of Asthma and COPD (GRIAC), University of Groningen, Groningen, The Netherlands
  1. Correspondence to J Elshof, Groningen, Groningen, The Netherlands; j.elshof{at}

Statistics from

Domiciliary nasal high-flow therapy in stable hypoxic COPD patients

Nasal high-flow (NHF) therapy has been shown to be a beneficial therapy for patients with acute respiratory failure in hospital and might be beneficial in patients with chronic hypoxemic respiratory failure if delivered at home. Storgaard et al. (Int J Chron Obstruct Pulmon Dis 2018;13:1195) performed a randomised controlled trial comparing NHF added to long-term oxygen therapy (LTOT+NHF) to LTOT alone in 200 moderately severe COPD patients. Compared with the previous year, patient-reported exacerbations increased from 2.90 to 4.95/patient/year in the LTOT alone group compared with a slight decrease from 3.23 to 3.12/patient/year in the LTOT+NHF group, resulting in a lower exacerbation frequency in the NHF group compared with the LTOT group (p<0.001). However, hospital admission and all-cause mortality were not different between the groups after 1 year. Exploratory analyses suggested that there was a dose response effect with a reduction in admissions in patients with high device usage. Furthermore, dyspnoea symptoms, health-related quality of life, arterial carbon dioxide pressure (PaCO2), and the 6 min walking distance improved in the NHF group compared with the LTOT group (all p<0.001). The study demonstrates that NHF is a potentially viable therapy in the home setting and may have physiological and clinical impact in patients with COPD on LTOT. Future studies should focus on high risk patients to assess the potential clinical impact on admission reduction.

CO2 clearance with nasal high-flow therapy in hypercapnic COPD patients is flow and leak dependent

Studies have shown that nasal …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.